Yeo lab:Projects: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
One of the major obstacles in translating potent drug candidates from bench to bedside is delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Research topics in my lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific projects involve (i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy. | One of the major obstacles in translating potent drug candidates from bench to bedside is delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Research topics in my lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific projects involve (i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy. | ||
|}<br style="clear:both" /> | |}<br style="clear:both" /> |
Revision as of 15:26, 23 September 2006
One of the major obstacles in translating potent drug candidates from bench to bedside is delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Research topics in my lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific projects involve (i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy. |